Not finding it? Sign in to also search OpenAlex live.
-
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2B and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Martín Rudwaleit, Irene E. van der Horst-Bruinsma, Floris A. van Gaalen, Nigil Haroon, Lianne S. Gensler, Myriam Manente, +4 more
0citations -
Antithrombotic Therapy Discontinuation, Bleeding, and Thromboembolic Events in Patients With Cancer During the Last Phase of Life: Insights From Primary Care Records2026 The Annals of Family Medicine article Medicine Venous Thromboembolism Diagnosis and Management Open access
Denise Abbel, Geert‐Jan Geersing, Emmy M. Trinks-Roerdink, Sarah J Aldridge, Adrian Edwards, Eric C. T. Geijteman, +15 more
0citations -
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +20 more
17citations -
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Jayesh Desai, Andrew J. Wagner, Irene Carrasco García, Marilena Cesari, Chia‐Chi Lin, Zsuzsanna Pápai, +11 more
10citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly2020 Journal of the Endocrine Society article Medicine Pituitary Gland Disorders and Treatments Open access
Susan Leanne Samson, Lisa B. Nachtigall, Maria Fleseriu, Murray B. Gordon, Mojca Jensterle, Atanaska P. Elenkova, +8 more
0citations -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
Andreas Burchert, Susanne Saußele, Stephan Metzelder, Andreas Hochhaus, Norbert Gattermann, Martina Margrit Crysandt, +27 more
13citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Gianantonio Rosti, Tim H. Brümmendorf, Bjørn Tore Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo B Gambacorti-Passerini, +6 more
10citations -
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study
Tim H. Brümmendorf, Patrick G. Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, +4 more
8citations -
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents
Andrew John Pollard, Odile Launay, Jean‐Daniel Lelièvre, Christine Lacabaratz, Sophie Grande, Neil H. Goldstein, +84 more
173citations -
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus
Fernando Ferrero, Chien‐Yu Lin, Johannes G. Liese, Kléber Giovanni Luz, T. Stoeva, Ágnes Németh, +14 more
15citations